{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-23-006560","form_type":"8-K","ticker":"AQST","cik":"0001398733","company_name":"Aquestive Therapeutics, Inc.","filed_at":"2023-03-06T23:59:59+00:00","discovered_at":"2026-05-14T18:03:44.752300+00:00","generated_at":"2026-06-18T11:20:35.003384+00:00","sec_items":["1.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Aquestive receives $11.5M payment from Indivior, extends commercial agreement to 2026","bullets":["Amendment No. 11 extends Commercial Exploitation Agreement with Indivior to August 16, 2026, with automatic one-year renewals.","Indivior paid $11.482 million, including $5.482M for 2022 and estimated 2023 price increases.","Amendment revises transfer pricing and payment terms for supplied product.","Agreement will not auto-renew after last product patent expires; earlier termination rights remain."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-23-006560","json":"https://secwatch.observer/filing/0001628280-23-006560.json","markdown":"https://secwatch.observer/filing/0001628280-23-006560.md","text":"https://secwatch.observer/filing/0001628280-23-006560.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1398733/000162828023006560/0001628280-23-006560-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1398733/000162828023006560/aqst-20230302.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-18T11:20:35.003384+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"1ff58f2e0950fede2300793c3cf1d034f79b21ba","claim":"Aquestive Therapeutics, Inc. amended Amendment No. 11 with Indivior Inc. valued at $11,482,000 (effective 2023-03-02).","evidence_excerpt":"Amendment No. 11 (the “Amendment”) to the Commercial Exploitation Agreement (the “Agreement’), dated as of August 15, 2008, with Indivior Inc.","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1398733/000162828023006560/0001628280-23-006560-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"amendment"},{"label":"Counterparty","value":"Indivior Inc."},{"label":"Value","value":"$11,482,000"},{"label":"Effective","value":"2023-03-02"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}